Phio Pharmaceuticals reports promising Phase 1b trial results for PH-762, showing complete tumor clearance in two patients with no significant adverse effects.
Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday – Here’s Why
Where Today's News Shapes Tomorrow
